Chlorocresol, an Additive to Commercial Succinylcholine, Induces Contracture of Human Malignant Hyperthermia-susceptible Muscles Via Activation of the Ryanodine Receptor Ca2+ Channel

Anesthesiology

Volumn 84, Issue 6, 1996, Pages 1380-1385

  Tegazzin, Vincenzo ^a   Scutari, Erica ^a   Treves, Susan ^b   Zorzato, Francesco ^b  

^a S ANTONIO HOSPITAL   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Hyperthermia, malignant; Ions, calcium: channels; Receptors, ryanodine

Indexed keywords

CAFFEINE; CALCIUM CHANNEL; CALCIUM ION; CHLOROCRESOL; DRUG ADDITIVE; DRUG PRESERVATIVE; HALOTHANE; RYANODINE RECEPTOR; SUXAMETHONIUM;

ANESTHESIA COMPLICATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG MIXTURE; HUMAN; HUMAN TISSUE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTURE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SARCOPLASMIC RETICULUM; VASTUS LATERALIS MUSCLE;

ANIMALS; CAFFEINE; CALCIUM; CALCIUM CHANNELS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE PROTEINS; NEUROMUSCULAR DEPOLARIZING AGENTS; RABBITS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SUCCINYLCHOLINE;

EID: 0029894482     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199606000-00014     Document Type: Article

References (27)

1. Gronert GA: Malignant hyperthermia. ANESTHESIOLOGY 1980; 53: 395-423
2. Johnson C, Edleman KJ: Malignant hyperthermia: A review. J Perinatol 1992; 11:61-71
3. Schwartz L, Rockoff M, Koka BV: Masseter spasm with anesthesia: Incidence and implications. ANESTHESIOLOGY 1984; 61:772-5
4. Endo M: Calcium release from the sarcoplasmic reticulum. Physiol Rev 1977; 7:71-108
5. Carafoli E: Intracellular calcium homcostasis. Ann Rev Biochem 1987; 56:395-433
6. Fujii J, Otsu K, Zorzato F, deLeon S, Khana VJ, Weiler JE, O'Brien PJ, MacLennan DH: Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448-51
7. MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodids W, Britt B, Worton RG: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343:559-61
8. Mckenzie AE, Korneluk RG, Zorzato F, Fujii J, Phillips M, Ile D, Wieringa B, LeBlond S, Bailly J, Willard HF, Duff C, Worton RG, MacLennan DH: The human ryanodine receptor gene: Its mapping to 19q13.1, placement in a chromosome linkage group, and exclusion as the gene causing myotonic dystrophy. Am J Hum Gen 1990; 46:1082-9
9. Takeshima H, Nishimura S, Matsumoto T, Ishida H, Kangawa K, Minamino N, Matsuo H, Ueda T, Hanakoa M, Hirose T, Numa S: Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature 1989; 339:439-45
10. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1990; 265: 2244-56
11. McCarthy TV, Healy JM, Heffron JA, Lehane M, Deufel T, Lehmann-Horn F, Farral M, Johnson K: Localization of the malignant herthermia susceptibility locus to human chromosome 19q12-q13.2. Nature 1990; 343:562-4
12. Lai FA, Erikson HP, Rousseau E, Liu QY, Meissner G: Purification and reconstitution of the calcium release channel from skeletal muscle. Nature 1988; 331:315-9
13. Fill M, Coronado R, Mickelson JR, Vilven J, Ma J, Jacobson BA, Louis CF: Abnormal ryanodine receptor channels in malignant hyperthermia. Biophys J 1990; 57:471-6
14. 2+ release channels in malignant hyperthermic skeletal muscle. Biophys J 1991; 59:1085-90
15. Palade P, Dettbarn C, Brunder D, Stein P, Hals G: Pharmacology of calcium release from sarcoplasmic reticulum. J Biomemb Bioenerg 1989; 21:295-320
16. European Malignant Hyperpyrexia Group: A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56:1267-9
17. Saito A, Seiler S, Chu A, Fleisher S: Preparation and morphology of sarcoplasmic reticulum terminal cisternae from rabbit skeletal muscle. J Cell Biol 1984; 99:875-85
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with Folin phenol reagents. J Biol Chem 1951; 193:265-75
19. 2+ release channel. J Biol Chem 1987; 262:6142-8
20. 2+ release. Mol Pharmacol 1993; 44:1192-1201
21. Fletcher JE, Rosenberg H: In vitro interaction between halothane and succinylcholine in human skeletal muscle: Implications for malignant hyperthermia and masseter muscle rigidity. ANESTHESIOLOGY 1985; 63:190-4
22. Lucke JN, Hall GM, Lister D: Porcine malignant hyperthermia: I. Metabolic and physiological changes. Br J Anaesth 1976; 48:297-304
23. Denborough MA, Forster JFA, Hudson MC, Carter NG, Zapf P: Biochemical changes in malignant hyperpyrexia. Lancet 1970; 1: 1137-40
24. Halsall PJ, Ellis FR: A screening test for the malignant hyperpyrexia phenotype using suxamethonium-induced contracture on muscle treated with caffeine and its inhibition by dantrolene. Br J Anaesth 1979; 51:753-6
25. Galloway GJ, Denborough MA: Suxamethonium chloride and malignant hyperthermia. Br J Anaesth 1986; 58:447-50
26. Bach MA, Blum DM, Rose SR, Charnas LR: Myalgia and elevated creatine kinase activity associated with subcutaneous injections of diluents. J Pediatr 1992; 121:650-1
27. Van Fassen I, Razenberg PP, Simoons-Smitt AM, van der Veen EA: Carriage of Staphylococcus aureus and inflamed infusion sites with insulin pump therapy. Diabetes Care 1989; 12:153-5